Bimatoprost

Generic Name: Bimatoprost

Brand Names: Durysta, Latisse, Lumigan

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₇NO_₄

CAS Number: 155206-00-1

Unique Ingredient Identifier: QXS94885MZ

Background: Bimatoprost, also known as Latisse or Lumigan, belongs to a group of drugs called prostamides, which are synthetic structural analogs of prostaglandin. Bimatoprost, marketed by Allergan, is administered in both the ophthalmic solution and implant form. It has the ability to reduce ocular hypotension, proving effective in conditions such as ocular hypertension and glaucoma. Bimatoprost is also used to treat eyelash hypotrichosis, or sparse eyelash growth. It was initially approved by the FDA in 2001 for ocular hypertension and later approved for hypothrichosis in 2008, as eyelash growth became a desirable adverse effect for patients using this drug.

Indication: Bimatoprost is used for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.

These patients must be intolerant to other intraocular pressure lowering medications or inadequately responsive to other treatments.

Bimatoprost is also indicated to treat eyelash hypotrichosis.

Associated Conditions: Hypotrichosis of the eyelashes, Increased Intra Ocular Pressure (IOP)

Clinical Trials

Triplenex (triple Fixed Combination) Use Evaluation in Patients with Glaucoma

Phase 4

Active, not recruiting

Conditions: Glaucoma
Quality of Life (QOL)

Interventions: Drug: Triple combination formula
Drug: Bimatoprost .03% sterile ophthalmic solution

First Posted Date: 2025-01-07

Last Posted Date: 2025-01-07

Lead Sponsor: Federal University of São Paulo

Target Recruit Count: 40

Registration Number: NCT06761313

Locations: 🇧🇷
Federal University of São Paulo, São Paulo, SP, Brazil

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Phase 1

Recruiting

Conditions: Open-angle Glaucoma
Ocular Hypertension

Interventions: Drug: LUMIGAN® (bimatoprost ophthalmic solution) 0.01%
Drug: Bimatoprost Ophthalmic Solution, 0.01%

First Posted Date: 2024-02-20

Last Posted Date: 2024-08-06

Lead Sponsor: Amneal Pharmaceuticals, LLC

Target Recruit Count: 240

Registration Number: NCT06267274

Locations: 🇺🇸
Houston Eye Associates, Houston, Texas, United States
🇺🇸
West Coast Eye Institute, Bakersfield, California, United States
🇺🇸
Eye Research Foundation, Newport Beach, California, United States

and more 1 locations

Treatment of Hypopigmented Scars With Bimatoprost

Phase 2

Recruiting

Conditions: Hypopigmented Scar
Hypopigmented Skin
Burn Scar
Pigmentation Disorder
Scars
Scarring
Cicatrix, Hypertrophic
Burns Laser
Cicatrix

Interventions: Drug: Saline
Drug: Bimatoprost

First Posted Date: 2023-11-08

Last Posted Date: 2024-05-03

Lead Sponsor: Medstar Health Research Institute

Target Recruit Count: 25

Registration Number: NCT06122090

Locations: 🇺🇸
MedStar Washington Hospital Center, Washington, District of Columbia, United States

Evaluation of the Bimatoprost Implant System Used in Combination With the SpyGlass Intraocular Lens Compared to Timolol Ophthalmic Solution

Phase 1

Active, not recruiting

Conditions: Ocular Hypertension
Glaucoma
Cataract

Interventions: Drug: Timolol Maleate Ophthalmic Solution, 0.5%
Drug: Bimatoprost Implant System (High Dose)
Drug: Bimatoprost Implant System (Low Dose)
Device: Commercially Available Aspheric Monofocal Non-Yellow Chromophore IOL
Device: SpyGlass IOL

First Posted Date: 2023-11-07

Last Posted Date: 2024-10-11

Lead Sponsor: SpyGlass Pharma, Inc.

Target Recruit Count: 201

Registration Number: NCT06120842

Locations: 🇺🇸
Arizona Advanced Eye Research Institute, Glendale, Arizona, United States

Systemic Pharmacokinetic Study of T4032 (Unpreserved Bimatoprost 0.01%) Eye Gel Versus Lumigan® 0.01% Eye Drops in 40 Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: Bimatoprost Ophthalmic

First Posted Date: 2023-02-15

Last Posted Date: 2023-11-14

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 40

Registration Number: NCT05729594

Locations: 🇺🇸
Biotrial, Newark, New Jersey, United States

Combined CO2 Fractional Laser With Bimatoprost 0.03% Treatment of Alopecia Areata

Phase 1

Completed

Conditions: Alopecia Areata

Interventions: Drug: Bimatoprost 0.03% solution
Device: CO2 fractional laser

First Posted Date: 2022-10-31

Last Posted Date: 2022-10-31

Lead Sponsor: Ahmed Hassan Nouh MD

Target Recruit Count: 30

Registration Number: NCT05600673

Locations: 🇪🇬
AL-Azhar University Hospital, Cairo, Egypt

Efficacy and Safety Assessment of T4032 (Unpreserved Bimatoprost 0.01%) Versus Lumigan® 0.01% in Ocular Hypertensive or Glaucomatous Patients

Phase 3

Completed

Conditions: Glaucoma
Ocular Hypertension

Interventions: Drug: Bimatoprost Ophthalmic

First Posted Date: 2022-05-31

Last Posted Date: 2024-07-18

Lead Sponsor: Laboratoires Thea

Target Recruit Count: 684

Registration Number: NCT05397600

Locations: 🇺🇸
Scheie Eye Institute - University of Pennsylvania, Philadelphia, Pennsylvania, United States
🇺🇸
Santa Barbara Eyecare - Santa Barbara, Santa Barbara, California, United States
🇺🇸
Ocala Eye - 3130 Location, Ocala, Florida, United States

and more 60 locations

Expanded Access to Bimatoprost (Durysta)

Conditions: Open-angle Glaucoma

First Posted Date: 2022-04-21

Last Posted Date: 2025-02-10

Lead Sponsor: AbbVie

Registration Number: NCT05338606

A Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant for Patients With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)

Phase 2

Completed

Conditions: Ocular Hypertension
Open Angle Glaucoma

Interventions: Drug: OTX-TIC low dose Travoprost Intracameral Implant
Drug: OTX-TIC high dose Travoprost Intracameral Implant
Drug: Durysta, Bimatoprost Intracameral Implant 10 µg

First Posted Date: 2022-04-19

Last Posted Date: 2025-03-21

Lead Sponsor: Ocular Therapeutix, Inc.

Target Recruit Count: 83

Registration Number: NCT05335122

Locations: 🇺🇸
Ocular Therapeutiux, Inc., Fargo, North Dakota, United States
🇺🇸
Ocular Therapeutix, Inc., Kenosha, Wisconsin, United States
🇺🇸
Ocular Therapeutix Inc, Oklahoma City, Oklahoma, United States

and more 1 locations

Intraocular Pressure Reduction Efficacy of Rhopressa and Lumigan in Normal Tension Glaucoma

Phase 4

Conditions: Normal Tension Glaucoma

Interventions: Drug: Netarsudil Ophthalmic
Drug: Bimatoprost Ophthalmic

First Posted Date: 2021-07-29

Last Posted Date: 2021-08-06

Lead Sponsor: Salus University

Target Recruit Count: 115

Registration Number: NCT04981886

Locations: 🇺🇸
Roberts Eyecare Associates, Vestal, New York, United States

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy